PriceTargets.com logo

HealthEquity - HQY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $103.83
  • Forecasted Upside: 18.52%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$87.61 As of 10/22/2024 01:00 AM ET
▼ -0.13 (-0.15%)

This chart shows the closing price for HQY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New HealthEquity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HQY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HQY

Analyst Price Target is $103.83
▲ +18.52% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for HealthEquity in the last 3 months. The average price target is $103.83, with a high forecast of $110.00 and a low forecast of $92.00. The average price target represents a 18.52% upside from the last price of $87.61.

This chart shows the closing price for HQY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in HealthEquity. This rating has held steady since September 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/20/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$105.00 ➝ $105.00
9/4/2024Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$102.00 ➝ $103.00
9/4/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$105.00 ➝ $105.00
9/4/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$92.00 ➝ $92.00
9/4/2024Bank of AmericaLower TargetBuy ➝ Buy$105.00 ➝ $100.00
8/30/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$105.00 ➝ $105.00
7/3/2024Bank of AmericaReiterated RatingBuy ➝ Buy$105.00 ➝ $105.00
6/20/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$107.00 ➝ $110.00
6/7/2024Raymond JamesBoost TargetOutperform ➝ Outperform$100.00 ➝ $105.00
6/5/2024KeyCorpBoost TargetOverweight ➝ Overweight$95.00 ➝ $100.00
6/4/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$105.00 ➝ $107.00
6/4/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$100.00 ➝ $105.00
6/4/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$92.00 ➝ $92.00
6/4/2024Bank of AmericaBoost TargetBuy ➝ Buy$97.00 ➝ $105.00
6/4/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$98.00 ➝ $104.00
6/4/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$101.00 ➝ $105.00
4/4/2024JMP SecuritiesInitiated CoverageMkt Outperform$101.00
4/2/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$86.00 ➝ $108.00
3/22/2024KeyCorpBoost TargetOverweight ➝ Overweight$85.00 ➝ $95.00
3/22/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$100.00
3/20/2024BTIG ResearchBoost TargetBuy ➝ Buy$100.00 ➝ $110.00
3/20/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$90.00 ➝ $92.00
3/20/2024Bank of AmericaBoost TargetBuy ➝ Buy$93.00 ➝ $97.00
2/23/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$77.00 ➝ $90.00
2/23/2024BarclaysBoost TargetOverweight ➝ Overweight$84.00 ➝ $104.00
1/3/2024BarclaysInitiated CoverageOverweight$84.00
12/13/2023Raymond JamesBoost TargetOutperform ➝ Outperform$90.00 ➝ $95.00
12/6/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$89.00 ➝ $93.00
12/4/2023Barrington ResearchReiterated RatingOutperform ➝ Outperform$85.00
12/1/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$81.00 ➝ $73.00
9/21/2023Robert W. BairdUpgradeNeutral ➝ Outperform$79.00 ➝ $87.00
9/7/2023Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$71.00 ➝ $72.00
9/6/2023Barrington ResearchBoost TargetOutperform ➝ Outperform$80.00 ➝ $85.00
9/6/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$75.00 ➝ $77.00
6/7/2023Deutsche Bank AktiengesellschaftBoost Target$69.00 ➝ $71.00
3/24/2023Deutsche Bank AktiengesellschaftLower TargetBuy$72.00 ➝ $69.00
3/22/2023Royal Bank of CanadaReiterated RatingOutperform$75.00
2/3/2023Wells Fargo & CompanyLower TargetOverweight$101.00 ➝ $89.00
1/24/2023Deutsche Bank AktiengesellschaftBoost TargetBuy$68.00 ➝ $72.00
12/12/2022Robert W. BairdBoost Target$75.00
12/12/2022Raymond JamesBoost TargetOutperform$75.00 ➝ $85.00
12/7/2022GuggenheimBoost TargetBuy$89.00 ➝ $94.00
12/7/2022Wells Fargo & CompanyLower TargetOverweight$104.00 ➝ $101.00
12/5/2022Royal Bank of CanadaBoost Target$70.00 ➝ $75.00
11/2/2022Jefferies Financial GroupBoost Target$80.00 ➝ $90.00
10/25/2022Wells Fargo & CompanyBoost TargetOverweight$100.00 ➝ $104.00
10/21/2022The Goldman Sachs GroupUpgradeSell ➝ Neutral$64.00 ➝ $77.00
9/15/2022KeyCorpInitiated CoverageOverweight$85.00
9/13/2022Wells Fargo & CompanyBoost TargetOverweight$95.00 ➝ $100.00
9/12/2022Raymond JamesBoost TargetOutperform$70.00 ➝ $75.00
9/8/2022Deutsche Bank AktiengesellschaftBoost TargetBuy$67.00 ➝ $68.00
9/7/2022Robert W. BairdBoost TargetNeutral$47.00 ➝ $67.00
7/12/2022The Goldman Sachs GroupInitiated CoverageSell$59.00
6/8/2022Deutsche Bank AktiengesellschaftBoost Target$66.00 ➝ $67.00
6/7/2022Barrington ResearchBoost Target$70.00 ➝ $75.00
6/7/2022Leerink PartnersBoost TargetOutperform$67.00 ➝ $76.00
4/11/2022Wells Fargo & CompanyInitiated CoverageOverweight$95.00
4/6/2022GuggenheimInitiated CoverageBuy$89.00
3/30/2022BTIG ResearchUpgradeNeutral ➝ Buy$85.00
3/28/2022Jefferies Financial GroupBoost TargetBuy$62.00 ➝ $80.00
3/24/2022Deutsche Bank AktiengesellschaftBoost TargetBuy$62.00 ➝ $66.00
3/23/2022Bank of AmericaBoost Target$63.00 ➝ $70.00
3/23/2022Barrington ResearchBoost Target$55.00 ➝ $70.00
2/24/2022Deutsche Bank AktiengesellschaftBoost TargetBuy$52.00 ➝ $62.00
12/21/2021JPMorgan Chase & Co.Lower TargetOverweight$82.00 ➝ $56.00
12/8/2021Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$75.00 ➝ $52.00
12/7/2021Barrington ResearchLower TargetOutperform ➝ Outperform$80.00 ➝ $55.00
12/7/2021Royal Bank of CanadaLower TargetOutperform ➝ Outperform$87.00 ➝ $70.00
12/7/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$90.00 ➝ $70.00
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$68.00
9/21/2021Deutsche Bank AktiengesellschaftLower TargetIn-Line ➝ Buy$92.00 ➝ $75.00
9/9/2021Barrington ResearchReiterated RatingBuy$90.00
9/9/2021Leerink PartnersUpgradeMarket Perform ➝ Outperform$80.00
7/1/2021StephensInitiated CoverageOverweight$100.00
6/10/2021Raymond JamesBoost TargetStrong-Buy$85.00 ➝ $90.00
6/8/2021BTIG ResearchReiterated RatingHold
6/8/2021Cantor FitzgeraldBoost TargetOverweight$82.00 ➝ $85.00
5/24/2021Robert W. BairdReiterated RatingNeutral ➝ Hold$86.00
4/29/2021JPMorgan Chase & Co.Initiated CoverageOverweight
3/22/2021Raymond JamesLower TargetStrong-Buy$100.00 ➝ $85.00
3/17/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$88.00 ➝ $92.00
3/16/2021Leerink PartnersBoost TargetMarket Perform$77.00 ➝ $80.00
2/10/2021Raymond JamesBoost TargetStrong-Buy$75.00 ➝ $100.00
2/9/2021Barrington ResearchReiterated RatingOutperform$75.00 ➝ $90.00
2/9/2021Truist FinancialBoost Target$80.00 ➝ $92.00
2/9/2021Royal Bank of CanadaBoost TargetOutperform$74.00 ➝ $87.00
1/6/2021BTIG ResearchInitiated CoverageNeutral
1/6/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$60.00 ➝ $77.00
12/8/2020Cantor FitzgeraldBoost TargetOverweight$70.00 ➝ $77.00
12/8/2020JPMorgan Chase & Co.Boost TargetOverweight$61.00 ➝ $72.00
12/8/2020Barrington ResearchBoost TargetOutperform$70.00 ➝ $75.00
12/8/2020Royal Bank of CanadaBoost TargetOutperform$67.00 ➝ $74.00
12/2/2020Leerink PartnersBoost TargetMarket Perform$64.00 ➝ $77.00
11/23/2020GuggenheimDowngradeBuy ➝ Neutral
10/23/2020Royal Bank of CanadaInitiated CoverageOutperform$67.00
9/10/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$57.00 ➝ $60.00
9/9/2020Barrington ResearchBoost TargetOutperform$65.00 ➝ $70.00
9/9/2020Wells Fargo & CompanyBoost TargetOverweight$63.00 ➝ $70.00
9/9/2020Leerink PartnersBoost TargetPositive ➝ Market Perform$51.00 ➝ $64.00
9/9/2020Raymond JamesReiterated RatingBuy
6/3/2020Cantor FitzgeraldLower TargetOverweight$80.00 ➝ $70.00
6/1/2020Barrington ResearchReiterated RatingBuy$65.00
4/20/2020Cantor FitzgeraldReiterated RatingBuy$80.00
4/14/2020GuggenheimInitiated CoverageBuy$56.00
4/13/2020Leerink PartnersInitiated CoverageMarket Perform$53.00
4/8/2020Raymond JamesLower TargetStrong-Buy$90.00 ➝ $75.00
3/27/2020Raymond JamesLower TargetReduce ➝ Strong-Buy$110.00 ➝ $90.00
3/26/2020SunTrust BanksBoost TargetBuy$55.00 ➝ $68.00
3/18/2020Deutsche Bank AktiengesellschaftLower TargetBuy$88.00 ➝ $57.00
3/17/2020Barrington ResearchLower TargetOutperform$86.00 ➝ $65.00
3/17/2020SunTrust BanksLower TargetBuy$87.00 ➝ $55.00
3/17/2020Robert W. BairdLower TargetNeutral$74.00 ➝ $47.00
3/17/2020KeyCorpLower TargetOverweight$86.00 ➝ $65.00
3/17/2020Cantor FitzgeraldReiterated RatingOverweight$90.00 ➝ $80.00
2/20/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$74.00 ➝ $88.00
2/19/2020Barrington ResearchReiterated RatingBuy$86.00
2/19/2020Wells Fargo & CompanyBoost TargetOverweight$80.00 ➝ $87.00
2/19/2020KeyCorpBoost TargetOverweight$80.00 ➝ $86.00
1/8/2020Wells Fargo & CompanyBoost TargetOverweight$76.00 ➝ $80.00
12/4/2019Cantor FitzgeraldReiterated RatingBuy$95.00
12/4/2019KeyCorpReiterated RatingBuy$70.00 ➝ $77.00
12/2/2019Barrington ResearchReiterated RatingBuy$75.00
(Data available from 10/23/2019 forward)

News Sentiment Rating

1.20 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 22 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 12 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024
  • 17 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2024
  • 21 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 21 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 10 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/24/2024
  • 31 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/23/2024
  • 24 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024

Current Sentiment

  • 24 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

HealthEquity logo
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.
Read More

Today's Range

Now: $87.61
Low: $86.73
High: $87.95

50 Day Range

MA: $79.44
Low: $71.16
High: $88.00

52 Week Range

Now: $87.61
Low: $61.81
High: $89.23

Volume

335,379 shs

Average Volume

613,145 shs

Market Capitalization

$7.62 billion

P/E Ratio

73.01

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of HealthEquity?

The following equities research analysts have issued reports on HealthEquity in the last twelve months: Bank of America Co., Barclays PLC, Barrington Research, BTIG Research, Deutsche Bank Aktiengesellschaft, JMP Securities, JPMorgan Chase & Co., KeyCorp, Raymond James, Robert W. Baird, Royal Bank of Canada, and Wells Fargo & Company.
View the latest analyst ratings for HQY.

What is the current price target for HealthEquity?

12 Wall Street analysts have set twelve-month price targets for HealthEquity in the last year. Their average twelve-month price target is $103.83, suggesting a possible upside of 18.5%. Wells Fargo & Company has the highest price target set, predicting HQY will reach $110.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $92.00 for HealthEquity in the next year.
View the latest price targets for HQY.

What is the current consensus analyst rating for HealthEquity?

HealthEquity currently has 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HQY will outperform the market and that investors should add to their positions of HealthEquity.
View the latest ratings for HQY.

What other companies compete with HealthEquity?

Other companies that are similar to HealthEquity include Shift4 Payments, CDK Global, Maximus, Nielsen and Envestnet. Learn More about companies similar to HealthEquity.

How do I contact HealthEquity's investor relations team?

HealthEquity's physical mailing address is 15 WEST SCENIC POINTE DRIVE SUITE 100, DRAPER UT, 84020. The company's listed phone number is (801) 727-1000 and its investor relations email address is [email protected]. The official website for HealthEquity is www.healthequity.com. Learn More about contacing HealthEquity investor relations.